重组人血管内皮抑制素联合紫杉醇和卡铂方案与TP方案治疗晚期卵巢癌的随机对照研究  

The Control Study of Endostar Combined With Paclitaxel and Carboplatin and TP Regimen in the Treatment of Advanced Ovarian Cancer

作　　者：殷晓燕 齐元玲[2] 任海朋[2] 于杰 

机构地区：[1]山东省潍坊市奎文区卫生计生监察大队,261041 [2]潍坊市人民医院肿瘤内科,261041 [3]潍坊市奎文区卫生和计划生育局,261041

出　　处：《中国继续医学教育》2015年第22期149-150,共2页China Continuing Medical Education

摘　　要：目的比较重组人血管内皮抑制素联合紫杉醇和卡铂方案与TP方案治疗晚期卵巢癌的疗效。方法将60例晚期卵巢癌患者随机分为实验组和对照组,分别采用重组人血管内皮抑制素联合TP方案和单纯TP方案治疗,比较其疗效。结果实验组总有效率(90.0%)高于对照组(66.7%)(P<0.05)。治疗后两组CAl25水平均明显降低(P<0.05),实验组降低幅度大于对照组(P<0.05)。实验组中位生存时间为(31.24±5.36)个月,对照组中位生存时间为(23.78±4.01)个月,差异有统计学意义(P<0.05)。结论恩度联合紫杉醇和卡铂方案治疗晚期卵巢癌可以提高肿瘤患者治疗效果,延长生存期。Objective To compare the efficacy of endostar combined with paclitaxel and carboplatin and TP regimen in the treatment of advanced ovarian cancer. Methods 60 cases of patients with advanced ovarian cancer were randomly divided into the experimental group and the control group, were treated with endostar combined with TP regimen and TP regimen, comparing its curative effect. Results The total effective rate of the experimental group （90.0%） was significantly higher than that of the control group （66.7%） （P〈0.05）. After treatment, the levels of CA125 were significantly decreased in the two groups （P〈0.05）, and the decrease in the experimental group was significantly higher than that in the control group （P〈0.05）. The median survival time in the experimental group was （31.24±5.36） months, the median survival time in the control group was （23.78±4.01）, the difference was statistically significant （P〈0.05）. Conclusion Endostar combined with paclitaxel alcohol and carboplatin in the treatment of advanced ovarian cancer can improve the therapeutic effect in patients with tumor, prolong survival.

关 键 词：晚期卵巢癌 重组人血管内皮抑制素 TP方案 疗效 

分 类 号：R737[医药卫生—肿瘤]